Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241557 | 0.89 | HRH3 (0.58) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL1921574 | 0.88 | HRH3 (0.70) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL6752172 | 0.87 | CYP1A2 (0.65) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL23053146 | 0.86 | CYP1A2 (0.69) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL5707525 | 0.84 | CYP1A2 (0.61) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL1392847 | 0.82 | CHRM2 (0.70) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL1677571 | 0.82 | CHRM2 (0.60) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL7004091 | 0.81 | HRH3 (0.79) | CYP1A2ALDH1A1CYP2C19HRH3LMNA | |
| SCHEMBL29583126 | 0.81 | — | — | |
| SCHEMBL10527 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | claimed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | claimed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | claimed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | claimed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000044216-A1 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | claimed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-4619915-A | ANTIINFECTION AGENTS | PFIZER INC. (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0178845-A2 | Peptide-substituted heterocyclic immunostimulants | PFIZER INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4264574-A | MICROCAPSULES CONTAINED IN SPHERES FOR TREATING VERTICO AND CEREBROVASCULAR DEFICIENCIES | CHERQUI JEAN S | 1981-04-28 | — | — | US | disclosed |
| US-4229428-A | FOR VERTIGO IN MENIERE'S SYNDROME | CHERQUI JEAN S | 1980-10-21 | — | — | US | disclosed |
| US-4159332-A | Prevention of or reduction in severity of myocardial infarction | UNIMED, INC. (US) | 1979-06-26 | — | — | US | disclosed |
| US-3996364-A | ANTISECRETORY | SMITHKLINE CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | CYP1A2 935/4885ALDH1A1 3647/4885CYP2C19 2761/4885 |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CASP5, CASP3, CASP7 | CYP1A2 1773/4885ALDH1A1 2828/4885CYP2C19 2440/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | CYP1A2 935/4885ALDH1A1 3647/4885CYP2C19 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.